We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sources say Cipla has asked the Indian government for indemnification and exemptions from price capping, bridging trials and basic customs duty, as the company seeks fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine.